Tesaro (Tesaro) Retained Earnings : $-1,936.4 Mil (As of Sep. 2018)

View and export this data going back to 2012. Start your Free Trial

What is Tesaro Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Tesaro's retained earnings for the quarter that ended in Sep. 2018 was $-1,936.4 Mil.

Tesaro's quarterly retained earnings declined from Mar. 2018 ($-1,632.7 Mil) to Jun. 2018 ($-1,799.4 Mil) and declined from Jun. 2018 ($-1,799.4 Mil) to Sep. 2018 ($-1,936.4 Mil).

Tesaro's annual retained earnings declined from Dec. 2015 ($-601.9 Mil) to Dec. 2016 ($-990.7 Mil) and declined from Dec. 2016 ($-990.7 Mil) to Dec. 2017 ($-1,469.9 Mil).

Tesaro Retained Earnings Historical Data

The historical data trend for Tesaro's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tesaro Retained Earnings Chart

Tesaro Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Retained Earnings

Get a 7-Day Free Trial

-179.50

-350.51

-601.92

-990.67

-1,469.89

Tesaro Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Retained Earnings	Get a 7-Day Free Trial															-1,287.82	-1,469.89	-1,632.70	-1,799.35	-1,936.44

Tesaro Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Tesaro (NAS:TSRO) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Tesaro (Tesaro) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tesaro Inc (NAS:TSRO) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.tesarobio.com

Tesaro is an oncology-focused biopharmaceutical company with a focus on developing treatments for cancer. Upon successful development and regulatory approval of any of its product candidates, the company intends to pursue commercialization in key product markets, including North America, Europe, and China. Tesaro is currently focused on commercializing products directly in North America, and directly or in partnership with established companies in Europe and China. The company's strategy is to identify, acquire, and develop promising drug candidates, and to commercialize cancer therapeutics that are potentially safer and more effective than existing treatments.

Executives

Mary Lynne Hedley	director, officer: President & COO	C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Kavita Patel	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Huber Martin H. Jr.	officer: SVP & Chief Medical Officer	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Moulder Leon O Jr	director, officer: Chief Executive Officer	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
James O Armitage	director	C/O TESARO, INC., 1000 WINTER ST., SUITE 3300, WALTHAM MA 02451
Timothy R Pearson	officer: Exec. VP, CFO	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Garry A Nicholson	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Grant C. Bogle	officer: Sr. VP, Chief Commercial Ofc	C/O TESARO, INC. 1000 WINTER STREET, SUITE 3300 WALTHAM MA 02451
Nea Partners 13, Limited Partnership	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea 13 Gp, Ltd	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
New Enterprise Associates 13 Lp	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Collier Earl M Jr	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Beth C Seidenberg	director
Joseph L Farmer	officer: Sr VP, Gen Counsel & Secretary	C/O TESARO, INC. 1000 WINTER STREET, SUITE 3300 WALTHAM MA 02451
Patrick J Kerins	10 percent owner